Yahoo Finance EN

BeOne Medicines (ONC) Reports $1.5B Revenue for Q4, $1.1B from Lymphoma Treatment

Mar 01, 2026 &03590101202631; 14:59 UTC finance.yahoo.com Trending 3/5

Read original on finance.yahoo.com ↗

↗

Positive for markets

Sentiment score: +90/100

High impact Short-term (days)

WHAT THIS MEANS

BeOne Medicines reported $1.5 billion in revenue for Q4, with $1.1 billion specifically from its lymphoma treatment, indicating strong product performance and market demand. This revenue surge is likely to boost investor confidence and positively impact the company's financial outlook.

AI CONFIDENCE

0% Low

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↑

ONC

ONCStock

Expected to rise

Exceptional Q4 revenue driven by high sales from lymphoma treatment, suggesting robust growth and profitability.

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

Consider accumulating ONC shares as the strong revenue report may lead to positive earnings revisions and stock price appreciation.

KEY SIGNALS

$1.5B Q4 revenue$1.1B from lymphoma treatment

SECTORS INVOLVED

Healthcare

Analysis generated on Mar 01, 2026 at 15:26 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Yahoo Finance. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

BeOne Medicines (ONC) Reports $1.5B Revenue for Q4, $1.1B from Lymphoma Treatment

RELATED INTELLIGENCE